Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fucoxanthin is a marine carotenoid (an epoxycarotenol) primarily found in brown seaweed and algae, responsible for their brown or olive-green color. It is available as a dietary supplement and has been investigated for multiple biological activities, including anti-inflammatory, antidiabetic, antioxidant, anti-obesity, antitumor/anticancer, hepatoprotective, neuroprotective, and cardiovascular protective effects[1][2][3][4]. Fucoxanthin exerts its effects through several mechanisms such as inducing cell cycle arrest (G0/G1 phase), promoting apoptosis in cancer cells by modulating the expression of cyclins (e.g., cyclin D), CDKs (e.g., CDK4), p15/p21 proteins[3][8], inhibiting angiogenesis via suppression of FGF2-mediated signaling pathways[6], regulating lipid metabolism likely through activation of AMP-activated protein kinase (AMPK)[1][2], and targeting PI3K/Akt/NF-kB signaling pathways[6]. Its exact anticancer mechanism remains incompletely elucidated. Clinical trials are ongoing to evaluate its efficacy in metabolic syndrome and non-alcoholic fatty liver disease[1][2]. Fucoxanthin can inhibit CYP3A4 enzyme activity which may affect the metabolism of other drugs[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fucoxanthin.